Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis von Croze, E, Yamaguchi, K D, Knappertz, V, Reder, A T, Salamon, H

Volltext

Interferon beta -1b-neutralizing antibodies 5 years after clinically isolated syndrome von Hartung, H-P, Freedman, MS, Polman, CH, Edan, G, Kappos, L, Miller, D H, Montalban, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V

Volltext

Aspirin and clopidogrel resistance: an emerging clinical entity von Johns, Anthony, Fisher, Matt, Knappertz, Volker

Volltext

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution von Filippi, M, Rocca, M A, Camesasca, F, Cook, S, O'Connor, P, Arnason, B G W, Kappos, L, Goodin, D, Jeffery, D, Hartung, H-P, Comi, G, Wolinsky, J S, Bogumil, T, Pohl, C, Beckmann, K, Sandbrink, R, Croze, E, Brown, C, Desimone, T M, Arnold, D L, Cutter, G, Knappertz, V

Volltext

Lack of hemispheric dominance for consciousness in acute ischaemic stroke von Cucchiara, B, Kasner, S E, Wolk, D A, Lyden, P D, Knappertz, V A, Ashwood, T, Odergren, T, Nordlund, A

Volltext

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial von Schippling, S, O'Connor, P, Knappertz, V, Pohl, C, Bogumil, T, Suarez, G, Cook, S, Filippi, M, Hartung, H P, Comi, G, Jeffery, D R, Kappos, L, Goodin, D S, Arnason, B

Volltext

The dose of aspirin for the prevention of cardiovascular and cerebrovascular events von Fisher, Matt, Knappertz, Volker

Volltext

Survival in MS von Goodin, D S, Reder, A T, Ebers, G C, Cutter, G, Kremenchutzky, M, Oger, J, Langdon, D, Rametta, M, Beckmann, K, DeSimone, T M, Knappertz, V

Volltext

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S von Kaufman, D.W, Reshef, S, Golub, H.L, Peucker, M, Corwin, M.J, Goodin, D.S, Knappertz, V, Pleimes, D, Cutter, G

Volltext

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis von Caloyeras, John P., MPhil, Zhang, Bin, MD, MSc, Wang, Cheng, MD, PhD, Eriksson, Marianne, MSc, Fredrikson, Sten, MD, PhD, Beckmann, Karola, MSc, Knappertz, Volker, MD, Pohl, Christoph, MD, Hartung, Hans-Peter, MD, Shah, Dhvani, MS, Miller, Jeffrey D., MS, Sandbrink, Rupert, MD, Lanius, Vivian, PhD, Gondek, Kathleen, PhD, Russell, Mason W., MAPE

Volltext

Multiple Sclerosis Patients Treated with IFNB-1b Express a Unique Isoform of the Oxidation Resistance Protein NCOA7 (P02.073) von Yu, L., Croze, E., Knappertz, V., Volkert, M.

Volltext

Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study von Doerner, M., Beckmann, K., Knappertz, V., Kappos, L., Hartung, H.P., Filippi, M., O'Connor, P.W., Arnason, B., Cook, S., Jeffery, D., Comi, G., Limmroth, V.

Volltext

Clinical Outcomes and Cause of Death for Interferon Beta-1b Versus Placebo, 21 Years Following Randomization (P04.129) von Reder, A., Goodin, D., Ebers, G., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., Knappertz, V.

Volltext

Mortality in Multiple Sclerosis in the United States (MIMS-US): A Retrospective, Cohort Study of Survival and Mortality Trends (P06.195) von Reshef, S., Cutter, G., Golub, H., Brueckner, A., Knappertz, V.

Volltext

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting m... von Acaster, S, Swinburn, P, Wang, C, Stemper, B, Beckmann, K, Knappertz, V, Pohl, C, Sandbrink, R, Gondek, K, Edan, G, Kappos, L, Freedman, M, Hartung, H-P, Arnason, B, Comi, G, Filippi, M, Jeffery, D, O’Connor, P, Cook, S, Lloyd, AJ

Volltext

Vagus nerve imaging with ultrasound: Anatomic and in vivo validation von Knappertz, Volker A., Tegeler, Charles H., Hardin, Sharon J., McKinney, William M.

Volltext

Cough headache and the competency of jugular venous valves von Knappertz, V A

Volltext

PND11 HEALTH ECONOMIC IMPACT OF EARLY TREATMENT OF MULTIPLE SCLEROSIS WITH DISEASE MODIFYING THERAPY von Curkendall, S, Wang, C, Johnson, BH, Cao, Z, Preblick, R, Torres, A, Knappertz, V, Gondek, K

Volltext

FP39-WE-01 Long-term follow-up 20 years after the pivotal interferon beta-1b multiple sclerosis trial von Goodin, D.S, Ebers, G, Cutter, G, Traboulsee, A, Langdon, D, Reder, A.T, Rametta, M, Knappertz, V

Volltext

ND4 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA von Caloyeras, JP, Harrow, B, Wang, C, Beckmann, K, Knappertz, V, Pohl, C, Miller, JD, Russell, MW, Sandbrink, R, Gondek, K

Volltext